Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Conte

Showing results (341-350 of 368) with videos related to

Pageof 37
Sort By:
Trials|February 5, 2016
Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 9, 2000
Effect of high-flux dialysis on the anaemia of haemodialysis patientsF Locatelli, S Andrulli, F Pecchini, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytesL Bonanno, A Pavan, M V Dieci, et al.
Trials|December 18, 2015
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
British Journal of Cancer|January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancerF Cappuzzo, F Mazzoni, A Gennari, et al.
Acta Physiologica (Oxford, England)|January 23, 2018
Four days of simulated shift work reduces insulin sensitivity in humansR Bescos, M J Boden, M L Jackson, et al.
The Pharmacogenomics Journal|July 6, 2016
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancerA Musolino, N Naldi, M V Dieci, et al.
Neuromuscular Disorders : NMD|February 14, 2017
PGM1 deficiency: Substrate use during exercise and effect of treatment with galactoseN C Voermans, N Preisler, K L Madsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancerM Venturini, A Michelotti, L Del Mastro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-OvestP F Conte, M Bruzzone, F Carnino, et al.
Pageof 37

Showing results (341-350 of 368) with videos related to

Sort By:
Pageof 37
Trials|February 5, 2016
Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 9, 2000
Effect of high-flux dialysis on the anaemia of haemodialysis patientsF Locatelli, S Andrulli, F Pecchini, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2018
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytesL Bonanno, A Pavan, M V Dieci, et al.
Trials|December 18, 2015
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialDenise A Yardley, Adam Brufsky, Robert E Coleman, et al.
British Journal of Cancer|January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancerF Cappuzzo, F Mazzoni, A Gennari, et al.
Acta Physiologica (Oxford, England)|January 23, 2018
Four days of simulated shift work reduces insulin sensitivity in humansR Bescos, M J Boden, M L Jackson, et al.
The Pharmacogenomics Journal|July 6, 2016
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancerA Musolino, N Naldi, M V Dieci, et al.
Neuromuscular Disorders : NMD|February 14, 2017
PGM1 deficiency: Substrate use during exercise and effect of treatment with galactoseN C Voermans, N Preisler, K L Madsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1996
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancerM Venturini, A Michelotti, L Del Mastro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-OvestP F Conte, M Bruzzone, F Carnino, et al.
Pageof 37